Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

First Posted Date
2024-10-17
Last Posted Date
2024-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
530
Registration Number
NCT06646276
Locations
🇨🇳

Local Institution - 0335, Xi'an, Shaanxi, China

🇺🇸

Local Institution - 0245, Fort Myers, Florida, United States

🇺🇸

Local Institution - 0009, Orange City, Florida, United States

and more 150 locations

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

First Posted Date
2024-10-11
Last Posted Date
2024-10-11
Lead Sponsor
Rima Patel
Target Recruit Count
15
Registration Number
NCT06637306
Locations
🇺🇸

Mount Sinai Health System, New York, New York, United States

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1100
Registration Number
NCT06632327

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
474
Registration Number
NCT06632977

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

First Posted Date
2024-10-08
Last Posted Date
2024-12-18
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
30
Registration Number
NCT06630325
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

First Posted Date
2024-10-04
Last Posted Date
2024-12-17
Lead Sponsor
AstraZeneca
Target Recruit Count
878
Registration Number
NCT06627647
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2024-10-02
Last Posted Date
2024-12-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
150
Registration Number
NCT06624059
Locations
🇨🇱

Centro de Estudios Clínicos SAGA, Santiago, Chile

🇨🇱

OrlandiOncología, Santiago, Chile

🇨🇱

Inst. Nacional Del Cancer; Servicio de Oncologia Medica, Santiago, Chile

and more 3 locations

A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

First Posted Date
2024-10-02
Last Posted Date
2024-12-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
680
Registration Number
NCT06623422
Locations
🇺🇸

Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States

🇺🇸

Thompson Cancer Survival Center ( Site 0168), Knoxville, Tennessee, United States

🇦🇺

Tasman Oncology Research ( Site 2104), Southport, Queensland, Australia

and more 6 locations

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

First Posted Date
2024-10-01
Last Posted Date
2024-12-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT06618014
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

First Posted Date
2024-09-23
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
750
Registration Number
NCT06607185
Locations
🇨🇳

Hsin-Chu Hospital, Hsin-chu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 21 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy